ProMIS Neurosciences

ProMIS Neurosciences AAQS

The The AAQS of ProMIS Neurosciences (PMN) as of Oct 27, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).

AAQS

4

YoY

0.00%

Last updated:

ProMIS Neurosciences has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock ProMIS Neurosciences in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The ProMIS Neurosciences AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2016
4.00 USD
Jan 1, 2017
4.00 USD
Jan 1, 2018
4.00 USD
Jan 1, 2019
4.00 USD
Jan 1, 2020
4.00 USD
Jan 1, 2021
4.00 USD
Jan 1, 2022
4.00 USD
Jan 1, 2023
4.00 USD
The ProMIS Neurosciences AAQS history
YEARAAQSYoY
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
4—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences develops precision medicine solutions targeting neurodegenerative diseases like Alzheimer’s, ALS, and MSA through proprietary antibody therapeutics. Its product portfolio includes PMN310 for amyloid-beta, PMN267 for TDP-43, and PMN442 for alpha-synuclein, leveraging its ProMIS and Collective Coordinates platforms to identify Disease Specific Epitopes on misfolded proteins. The company focuses on early detection and treatment, with plans to expand into Parkinson's and dementia with Lewy bodies. Its wholly owned subsidiary, ProMIS Neuro, supports these therapeutic development efforts. The firm generates revenue through the development and potential commercialization of its antibody therapeutics, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for neurodegenerative conditions. Its focus on misfolded proteins in diseases like AD, ALS, and MSA positions it to address unmet medical needs in specialized therapeutic segments. The company’s approach combines computational discovery with antibody development to create targeted solutions for complex neurological disorders. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProMIS Neurosciences stock

The AAQS of ProMIS Neurosciences is 4 in 2023.

On Eulerpool you can find the complete historical development of The AAQS ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — ProMIS Neurosciences

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — ProMIS Neurosciences